

First product use and sales of CelGro® in Poland

- Achieved **first product use and sales** of CelGro® in Poland for dental bone and soft tissue repair
- This achievement follows the **recent appointment of Komak as exclusive distributor in Poland and first product use and sales in the UK**
- Growing momentum in CelGro®'s commercialisation plans underpinned by **continuing discussions with potential product distribution partners in key EU markets**

Perth, Australia; 31 May 2018: Regenerative medicine company Orthocell Limited (ASX:OCC, "Orthocell" or the "Company") is pleased to announce the first product usage and sales of CelGro® in Poland, following the recent appointment of Komak Sp ("Komak") as its exclusive distributor of CelGro® for dental bone and soft tissue repair in Poland.

Orthocell Managing Director Paul Anderson said: *"The interest in CelGro® for bone and soft tissue repair in Poland is very encouraging. We are pleased that Komak has rapidly progressed the distributor agreement to first sales and believe they are well positioned to drive adoption of CelGro® in Poland."*

This achievement is a significant milestone for the Company and represents a valuable opportunity for Orthocell to demonstrate the favourable handling characteristics and superior clinical outcomes CelGro® offers.

Komak has initiated targeted education and promotional activities, as well as progressed in expanding the network of referring periodontists and oral and maxillofacial surgeons. Poland is an attractive emerging market, with a rapid uptake of innovative medical devices and a growing healthcare expenditure per capita. Orthocell is well positioned to gain traction in this exciting market and to expand into other fast growing European markets.

Orthocell continues to execute on its clear commercialisation strategy to drive product adoption and sales of CelGro® in Europe. Following the recent appointments to the Medical Scientific Advisory Board and engagement of first distributors in Italy and Poland, Orthocell is currently finalising further commercial partner agreements for product distribution in the UK and drive sales in key markets.



For more information, please contact:

General enquiries

Paul Anderson

Orthocell Limited
Managing Director

P: +61 8 9360 2888

E: paulanderson@orthocell.com.au

Investor enquiries

Joel Seah

Vesparum Capital

P: +61 3 8582 4800

E: orthocell@vesparum.com

Media enquiries

Haley Chartres

Hales² Communications

P: +61 423 139 163

E: haley@h-squared.com.au

About Orthocell Limited

Orthocell is a regenerative medicine company focused on regenerating mobility for patients by developing products for the repair of a variety of soft tissue injuries. Orthocell's portfolio of products include TGA-licensed cell therapies Autologous Tenocyte Implantation (Ortho-ATI®) and Autologous Chondrocyte Implantation (Ortho-ACI®), which aim to regenerate damaged tendon and cartilage tissue. The Company's other major product is CelGro®, a collagen medical device which facilitates tissue repair and healing in a variety of orthopaedic, reconstructive and surgical applications. Orthocell recently received European regulatory approval (CE Mark) for CelGro®. The collagen medical device can now be marketed and sold within the European Union for a range of dental bone and soft tissue regeneration procedures and is being readied for first approval in the US.

For more information on Orthocell, please visit www.orthocell.com.au or follow us on Twitter [@OrthocellLtd](https://twitter.com/OrthocellLtd) and LinkedIn www.linkedin.com/company/orthocell-ltd

